Literature DB >> 32789587

Outcomes of robotic esophagectomies for esophageal cancer by hospital volume: an analysis of the national cancer database.

Jonathan J Hue1, Katelynn C Bachman1, Stephanie G Worrell1, Kelsey E Gray1, Philip A Linden1, Christopher W Towe2.   

Abstract

BACKGROUND: Robotic minimally invasive esophagectomies (RMIE) have been associated with superior outcomes; however, it is unclear if these are specific to robotic technique or are present only at high-volume institutions. We hypothesize that low-volume RMIE centers would have inferior outcomes.
METHODS: The National Cancer Database (NCDB) identified patients receiving RMIE from 2010 to 2016. Based on the total number of RMIE performed by each hospital system, the lowest quartile performed ≤ 9 RMIE over the study period. Ninety-day mortality, number of lymph nodes evaluated, margins status, unplanned readmissions, length of stay (LOS), and overall survival were compared. Regression models were used to account for confounding.
RESULTS: 1565 robotic esophagectomies were performed by 212 institutions. 173 hospitals performed ≤ 9 RMIE (totaling 478 operations over the study period, 30.5% of RMIE) and 39 hospitals performed > 9 RMIE (1087 operations, 69.5%). Hospitals performing > 9 RMIE were more likely to be academic centers (90.4% vs 66.2%, p < 0.001), have patients with advanced tumor stage (65.3% vs 59.8%, p = 0.049), andadministered preoperative radiation (72.8% vs 66.3%, p = 0.010). There were no differences based on demographics, nodal stage, or usage of preoperative chemotherapy. On multivariable regressions, hospitals performing ≤ 9 RMIE were associated with a greater likelihood of experiencing a 90-day mortality, a reduced number of lymph nodes evaluated, and a longer LOS; however, there was no association with rates of positive margins or unplanned readmissions. Median overall survival was decreased at institutions performing ≤ 9 RMIE (37.3 vs 51.5 months, p < 0.001). Multivariable Cox regression demonstrated an association with poor survival comparing hospitals performing ≤ 9 to > 9 RMIE (HR 1.327, p = 0.018).
CONCLUSION: Many robotic esophagectomies occur at institutions which performed relatively few RMIE and were associated with inferior short- and long-term outcomes. These data argue for regionalization of robotic esophagectomies or enhanced training in lower volume hospitals.

Entities:  

Keywords:  Esophageal cancer; Esophagectomy; Outcomes; Regionalization; Robotic

Year:  2020        PMID: 32789587     DOI: 10.1007/s00464-020-07875-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  4 in total

1.  Prolonged postoperative length of stay is associated with poor overall survival after an esophagectomy for esophageal cancer.

Authors:  Longfei Ma; Jingpei Li; Longlong Shao; Dong Lin; Jiaqing Xiang
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

2.  Esophageal Cancer and Surgical Margins: When a Positive Is a Negative.

Authors:  Stephanie G Worrell
Journal:  Ann Surg Oncol       Date:  2020-01-03       Impact factor: 5.344

3.  Modular step-up approach to robot-assisted transthoracic esophagectomy-experience of a German high volume center.

Authors:  Hans F Fuchs; Dolores T Müller; Jessica M Leers; Wolfgang Schröder; Christiane J Bruns
Journal:  Transl Gastroenterol Hepatol       Date:  2019-08-23

4.  Robot-Assisted Hybrid Esophagectomy Is Associated with a Shorter Length of Stay Compared to Conventional Transthoracic Esophagectomy: A Retrospective Study.

Authors:  Hans C Rolff; Rikard B Ambrus; Mohammed Belmouhand; Michael P Achiam; Marianne Wegmann; Mette Siemsen; Steen C Kofoed; Lars B Svendsen
Journal:  Minim Invasive Surg       Date:  2017-12-06
  4 in total
  1 in total

Review 1.  Intraoperative fluorescence imaging in esophagectomy and its application to the robotic platform: a narrative review.

Authors:  Marianna V Papageorge; Uma M Sachdeva; Lana Y Schumacher
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.